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The effect of protein binding in an "extravascular" space on antimicrobial pharmacodynamics was studied
in an in vitro capillary model of infection. Simulated 500-mg oral doses of dicloxacillin (-96% bound) or
cephalexin (<5% bound) were administered every 6 h for four doses. A 10-fold-higher dose of dicloxacillin was
also studied to determine the effect of drug concentration on the reduction of bacterial killing in the presence
of protein. Staphylococcus aureus ATCC 25923 was inoculated into peripheral chambers filled with either
Mueller-Hinton broth or Mueller-Hinton broth plus 25% human serum. Serial samples for bacterial counts
were collected over 24 h. The presence of serum in the chambers significantly reduced bacterial killing by
dicloxacillin but not by cephalexin during the first 6 h (two-way analysis of variance, F = 6.04, P < 0.05) but
not at 24 h. Reduction of dicloxacillin activity in serum-containing chambers persisted with the higher dose.
These data suggest that despite attaining higher total drug concentrations in protein-containing extravascular
spaces with highly bound drugs, protein binding reduces bactericidal activity during the early stages of
treatment in this model.
The clinical significance of the reduction of antibacterial
activity associated with the binding of drugs to human
proteins remains controversial. Despite considerable discus-
sion, only a few examples in humans (8, 10, 25) and in animal
models of infection (18, 20) have demonstrated the signifi-
cance of high plasma protein binding on treatment outcome.
Studies in animals (6, 19, 20), in vitro models (21), and
humans (16, 22, 25) have shown that high serum protein
binding significantly affects the kinetics of extravascular
drug distribution. High binding to serum proteins (e.g.,
albumin) in the intravascular space tends to reduce the
amount of drug available for diffusion into extravascular
spaces (22, 25). However, a considerable amount of serum
protein also is distributed to the extravascular space; for
example, approximately 60% of the total exchangeable albu-
min in the body is found in the extravascular space, but at
lower concentrations than in the intravascular space (17).
These proteins can bind a drug and result in higher concen-
trations of total (i.e., bound plus unbound) drug than those
observed in protein-free spaces (2, 9, 11, 19, 21).
There are few data on the effect of protein binding in an
infected extravascular space on antibacterial pharmacody-
namics following multiple simulated human doses. There-
fore, the pharmacodynamics of simulated doses of a highly
protein-bound drug (dicloxacillin) was compared with that of
a drug with negligible protein binding (cephalexin) in an in
vitro model of infection. The results show that during the
early stages of treatment, high protein binding significantly
retards the antimicrobial effects of dicloxacillin.
MATERIALS AND METHODS
Drugs. Cephalexin and dicloxacillin analytical-grade pow-
ders were supplied by Eli Lilly & Co., Indianapolis, Ind.
Stock solutions were prepared in appropriate amounts of
sterile, distilled, deionized water, which was further diluted
in Mueller-Hinton broth (MHB) for dose administration.
* Corresponding author.
Bacteria. Staphylococcus aureus ATCC 25923 was used as
the test strain. Susceptibility testing was done by the method
of Stratton and Reller (24), with the exception that serum-
supplemented medium (MHB-SER) was 75% MHB and 25%
human serum. The MIC and MBC for dicloxacillin against
this strain in MHB were 0.25 ,g/ml; in MHB-SER, they
were 2 and 8 ,ug/ml, respectively. The MIC and MBC for
cephalexin against this strain were 4 and 8 ,ug/ml, respec-
tively, in both MHB and MHB-SER.
Protein binding. The binding of dicloxacillin in MHB-SER
was measured with an Amicon MPS-1 unit with YMT
membranes (Amicon Corp., Danvers, Mass.). Dicloxacillin
was prepared in MHB-SER, and approximately 1 ml was
added to ultrafiltration units. Samples were centrifuged for
20 min at 1,000 x g (swinging bucket) at 37°C. The ultrafil-
trate was collected and assayed for dicloxacillin content by
agar well diffusion assay using Bacillus subtilis.
In vitro capillary model of infection. A two-compartment in
vitro model was modified to simulate first-order oral absorp-
tion with peak concentrations occurring 1 h after a dose (3,
4). The total volume of each peripheral ("extravascular")
compartment was 10 ml. The dilution rate was adjusted to
obtain a half-life of 1 h in the central compartment for both
drugs. The human pharmacokinetics of free (i.e., non-pro-
tein-bound) concentrations obtained with 500-mg doses of
cephalexin or dicloxacillin given every 6 h was simulated in
the central compartment of the model (Table 1) (9, 14, 15).
To determine the effect of the dose on the pharmacodynamic
properties of the more highly protein-bound drug, dicloxacil-
lin, a 10-fold-higher dose (D 10) also was studied.
The effect of extravascular protein binding on pharmaco-
dynamics was studied by filling peripheral chambers with
either 100% MHB or MHB-SER. A single pool of heat-
inactivated serum collected from healthy human volunteers
was used. Pilot studies showed that the protein binding of
dicloxacillin (concentrations of 10 jig/ml and lower) aver-
aged 95.5% in MHB-SER and was not detectable in MHB.
Binding of cephalexin to proteins in these media was as-
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TABLE 1. Predicted pharmacokinetic conditions at equilibrium for cephalexin and two dicloxacillin regimens in model experiments
Free drug Total drug in peripheral
Drug and dose In central compartment In all peripheral chambers chambers with 25% serum
regimen
Peak concn % of dosing interval with Cavg" AUCb Cavg AUC
(>g/ml) drug concn >MIC (,g/ml) (,u.g. h/ml) (p.g/ml) (>g- h/ml)
Cephalexin (C 20C) 20 70 9.7 58 9.7 58
Dicloxacillin
D 1c 1 62 0.5 2.9 11.1 64.4
D 10 10 100 4.8 29 107 644
a Cavg, average drug concentration derived from area under concentration-time curve divided by dosing interval.
b Area under the drug concentration versus time curve during a 6-h dosage interval at equilibrium.
c See legends to Fig. 1 and 2.
sumed to be negligible (less than 5%) (9). Protein concentra-
tions in peripheral chambers containing MHB-SER were
compared at 0 and either 24 or 30 h after the start of an
experiment by using a refractometer (Schuco, Williston
Park, N.Y.).
Bacteria from previously frozen inocula of approximately
4 x 107 CFU/ml were thawed, diluted with an equal part of
fresh MHB, and incubated at 37°C for 90 min to bring
organisms into the log-linear growth phase. A sample of this
mixture (0.3 ml) was injected into peripheral chambers
containing either MHB or MHB-SER; organisms were
grown in the chambers for approximately 1 h prior to the
administration of the first drug dose in order to obtain a final
inoculum of ca. 5 x 105 to 10 x 105 CFU/ml. Samples (ca.
0.3 ml) were collected from peripheral chambers, and bac-
terial counts (CFU per milliliter) were determined by plating
serial 10-fold saline dilutions of the sample on drug-free
Mueller-Hinton agar. The limit of detection of bacterial
growth was 10 CFU/ml.
Statistics. The significance of changes in the pharmacody-
namic properties of cephalexin and dicloxacillin with serum
supplementation (i.e., protein binding) or an increased dose
of dicloxacillin was determined by using two-factor analysis
of variance (23).
RESULTS
Figure 1 depicts the control growth of bacteria in both
MHB and MHB-SER and the pharmacodynamic properties
of four simulated 500-mg doses of cephalexin in chambers
with or without serum. Growth of unexposed organisms was
similar in both media. The first doses of cephalexin resulted
in an approximately 90% reduction of the initial inoculum
during the first 6 h; the reduction in CFU per milliliter was
similar in MHB and MHB-SER. Three subsequent doses
resulted in no significant reduction in CFU per milliliter for
the remainder of the study.
In contrast to the effect of cephalexin, the inhibitory effect
of dicloxacillin on bacterial growth was delayed in chambers
containing MHB-SER (Fig. 2). Analysis of bacterial counts
obtained at 6 h by two-factor analysis of variance (cepha-
lexin versus dicloxacillin and MHB versus MHB-SER) dem-
onstrated that the reduction of the antibacterial effect of
dicloxacillin by serum was statistically significant compared
with that for cephalexin (F = 6.04, 1 df; P < 0.05); however,
this difference was not statistically significant at 24 h (F =
5.14, 1 df; P > 0.05).
To determine if the reduction in dicloxacillin pharmaco-
dynamics in serum-supplemented media could be offset by
higher drug concentrations, a 10-fold-higher dose was stud-
ied (Fig. 2, D 10). In MHB-containing chambers, the higher
dose resulted in an increase in bacterial killing; however, at
6 h, a reduction in antimicrobial activity was still noted in
chambers with MHB-SER and was not altered by dose size
(F = 0.67, 1 df; P > 0.05 in the two-factor analysis of
variance for low dose versus high dose and MHB versus
MHB-SER). After 6 h, bacterial counts declined at similar
rates with both dose levels in MHB and MHB-SER cham-
bers.
There was no change in the MICs for dicloxacillin in
bacteria recovered at 30 h following exposure to the high- or
low-dose regimens. Protein concentrations at 24 and 30 h in
peripheral chambers containing MHB-SER varied from their
baseline value on average (n = 2) by 7.5 to 16% (range, 5.3
to 21%).
DISCUSSION
Reduced activity of highly bound antimicrobial agents in
vitro in the presence of serum proteins has led to speculation
that these agents would have reduced activity in vivo (8, 9).
Merrikin et al. evaluated several isoxazolyl penicillins with
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FIG. 1. Effect of extravascular protein binding on antibacterial
effect of cephalexin against S. aureus ATCC 25923 in a two-
compartment in vitro capillary model. Simulated oral doses were
administered every 6 h (arrows). The presence of serum (C 20/SER)
did not alter the antibacterial effect of 500-mg doses of cephalexin in
serum-free chambers (C 20/MHB). Control growth of untreated
bacteria was similar in MHB- and MHB-SER-containing chambers.
Datum points indicate the mean and 1 standard deviation.
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FIG. 2. Effect of extravascular protein binding on antibacterial
effect of dicloxacillin against S. aureus ATCC 25923 in a two-
compartment in vitro capillary model. Simulated oral doses were
given every 6 h (arrows). Dosage regimens provided peak concen-
trations of 1 ,ug/ml (500-mg dose [D 1]) and 10 ,ug/ml (D 10).
Chambers with serum (SER) showed a reduced effect of dicloxacil-
lin compared with serum-free chambers. Datum points indicate the
mean and 1 standard deviation.
similar MICs for a strain of S. aureus but various degrees of
plasma protein binding in experimentally induced peritonitis
in mice (18). Their study demonstrated that the curative dose
for 50% of mice for each agent increased with progressive
protein binding, indicating the need for large doses to obtain
adequate free-drug concentrations. Chambers et al. reported
the failure of single daily doses of cefonicid, a highly
protein-bound cephalosporin, in intravenous drug abusers
with tricuspid valve endocarditis due to S. aureus (7);
subsequent studies showed that high, saturable serum pro-
tein binding accelerates the decline of unbound-drug concen-
trations, resulting in prolonged periods of subtherapeutic
drug concentrations with single daily dosing (10). Others
have implicated high protein binding in the poor response of
a variety of infections treated with both high- and low-dose
regimens of cefoperazone, ceftriaxone, fusidic acid, and
teicoplanin (8, 12, 25).
While these earlier studies primarily focused on protein
binding in the intravascular space, we chose to study the
effect of protein binding in a simulated infected tissue site.
The presence of serum in simulated extravascular spaces did
not alter the antibacterial effect of cephalexin; this is consis-
tent with the low protein binding of this agent. In contrast,
the pharmacodynamic properties of dicloxacillin were signif-
icantly reduced in serum-supplemented chambers; this re-
duction persisted despite the use of a 10-fold-higher dose.
This latter observation is remarkable since the higher-dose
regimen (D 10) was designed to result in ratios of the drug
concentration to the MIC in serum-containing chambers
similar to those obtained with the lower-dose regimen for
serum-free chambers (i.e., for D 10 the central peak was 10
,ug/ml and the MIC in MHB-SER was 2 ,ug/m [ratio, 5], while
for the 500-mg dose the central peak was 1 ,ug/ml and the
MIC in MHB-SER was 0.25 ,ug/ml [ratio, 4]).
Antagonism to dicloxacillin activity by serum was most
pronounced during the first dosage interval. These observa-
tions are consistent with a high binding capacity for the drug
in the peripheral compartment coupled with a slow drug
transfer from the central compartment. In this model, the
onset of antibacterial effects was delayed because of a delay
in the accumulation of adequate free-drug concentrations at
the site of infection (6, 11, 19); this occurs because a large
proportion of dicloxacillin diffusing to the site of infection is
immediately bound to serum proteins. These data suggest
that the onset of the antibacterial effects of highly bound
antibiotics is delayed in the presence of binding proteins at
the site of infection. A delay in the onset of antibacterial
effects might be most important in the setting of surgical
prophylaxis, in which the protective effect is greatest when
therapeutic drug concentrations are present in extravascular
tissues at the time of bacterial inoculation (1, 5). However,
the large amount of drug ultimately accumulating in periph-
eral protein-containing extravascular spaces results in a
relatively more protracted antibacterial effect following the
suspension of treatment, since drug concentrations tend to
decline more slowly under these conditions (6, 11, 13).
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